ClinicalTrials.gg

Program

Terbinafine

Also written as “MOB015B”, “terbinafine” and “Terbinafine Hydrochloride”.

Its studies are mostly in Onychomycosis · Erythema · Tinea Pedis · Mycoses · Fasting, led by 13 companies.

Furthest: phase 3, since Aug 4, 201633 company-led studies, 2 open or runningNext primary completion: Jan 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Moberg Pharma AB71 open or runningphase 3since Aug 4, 2016Mar 15, 2013none ahead
Novartis70 open or runningphase 3since Jun 30, 2005Nov 2, 1999none ahead
Almirall30 open or runningphase 3since Sep 8, 2015Sep 8, 2015none ahead
Celtic Pharma Development Services20 open or runningphase 3since Mar 19, 2010Mar 18, 2010none ahead
Dr. Reddy's Laboratories20 open or runningphase 1since Jan 26, 2011Jan 26, 2011none ahead
Hikma Pharmaceuticals20 open or runningno phasesince Jan 15, 2008Jan 15, 2008none ahead
Nitric BioTherapeutics20 open or runningphase 2since Mar 1, 2010Mar 1, 2010none ahead
Teva Pharmaceutical Industries20 open or runningphase 1since Jan 30, 2009Jan 30, 2009none ahead
Viatris20 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
GlaxoSmithKline10 open or runningphase 1since Jan 17, 2013Jan 17, 2013none ahead
nexmed-u-s-a-inc-subsidiary-of-apricus-biosciences-inc10 open or runningphase 1since Jun 3, 2008Jun 3, 2008none ahead
Onyx Axiom11 open or runningphase 2since Nov 20, 2025Nov 20, 2025Jan 2028phase 2 · NCT07382427
united-laboratories10 open or runningphase 2since Jun 24, 2019Jun 24, 2019none ahead

Also a collaborator on its studies: ppd-development-lp.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 14 studies since Nov 2, 1999.

  1. Mar 18, 2010Celtic Pharma Development Services's first study: phase 2 study in OnychomycosisNew to Celtic Pharma Development ServicesCeltic Pharma Development Services · NCT01790165 · 27 enrolled
  2. Mar 19, 2010Phase 3 study in OnychomycosisCeltic Pharma Development Services · NCT01145807 · 738 enrolled · United States
  3. Jan 26, 2011Dr. Reddy's Laboratories's first studies: 2 phase 1 studiesNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01286701, NCT01286688
  4. Sep 8, 2011Phase 3 study in Tinea PedisNovartis · NCT01433107 · 290 enrolled · China
  5. Nov 28, 2011Phase 2 study in OnychomycosisNitric BioTherapeutics · NCT01484145 · 25 enrolled · United States
  6. Jan 17, 2013GlaxoSmithKline's first study: phase 1 study in MycosesNew to GlaxoSmithKlineGlaxoSmithKline · NCT01772212 · 30 enrolled
  7. Mar 15, 2013Moberg Pharma AB's first study: phase 2 study in Distal Subungual OnychomycosisNew to Moberg Pharma ABMoberg Pharma AB · NCT01814020 · Sweden
  8. Sep 8, 2015Almirall's first studies: 2 phase 3 studies in OnychomycosisNew to AlmirallAlmirall · NCT02549001, NCT02547701
  9. Aug 4, 20162 phase 3 studies in Distal Subungual OnychomycosisMoberg Pharma AB · NCT02859519, NCT02866032
  10. Mar 21, 2017Phase 3 study in Onychomycosis of ToenailAlmirall · NCT03094468 · United States, Canada
  11. Aug 1, 20173 phase 1 studiesMoberg Pharma AB · NCT06369727, NCT06369675, NCT03244280
  12. Jun 24, 2019united-laboratories's first study: phase 2 study in Tinea PedisNew to united-laboratoriesunited-laboratories · NCT03999437 · 42 enrolled · Philippines
  13. Mar 4, 2022Phase 3 study in OnychomycosisMoberg Pharma AB · NCT05279846 · 350 enrolled · United States, Canada
  14. Nov 20, 2025Onyx Axiom's first study: phase 2 study in Onychomycosis of ToenailNew to Onyx AxiomOnyx Axiom · NCT07382427 · 200 planned

Ahead

  1. Jan 2028Primary completion: phase 2 study in Onychomycosis of ToenailOnyx Axiom · NCT07382427

TargetBeta

SQLE →read by rule
“Squalene monooxygenase inhibitor; Squalene monooxygenase inhibitor”ChEMBL 37, by rule
“Terbinafine is a long-licensed, generic antifungal drug that inhibits squalene epoxidase (SQLE), an enzyme that may play a role in prostate cancer progression.”study text, by rule · the study

Studies

All 33 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07382427Onychomycosis of Toenail2Not yet recruitingOnyx AxiomJan 2028200
NCT05279846Onychomycosis · United States, Canada3Active, not recruitingMoberg Pharma ABJan 2025350
NCT03999437Tinea Pedis · Philippines2UNKNOWNunited-laboratoriesDec 13, 201942
NCT06369727Erythema · United States1CompletedMoberg Pharma ABFeb 15, 2018250
NCT06369675Erythema · United States1CompletedMoberg Pharma ABNov 14, 201745
NCT03244280Onychomycosis · United States1CompletedMoberg Pharma ABApr 23, 201820
NCT03094468Onychomycosis of Toenail · United States, Canada3WithdrawnAlmirallOct 20190
NCT02866032Distal Subungual Onychomycosis · Germany, Poland, United Kingdom3CompletedMoberg Pharma ABJun 10, 2020452
NCT02859519Distal Subungual Onychomycosis · United States, Canada3CompletedMoberg Pharma ABNov 13, 2019365
NCT02549001Onychomycosis · Belgium, Bulgaria, Czechia and more3CompletedAlmirallSep 17, 2018953
NCT02547701Onychomycosis · Belgium, Germany, Italy and more3CompletedAlmirallSep 201720
NCT01814020Distal Subungual Onychomycosis · Sweden2CompletedMoberg Pharma ABJul 2014
NCT01772212Mycoses1CompletedGlaxoSmithKlineMar 15, 201130
NCT01484145Onychomycosis · United States2CompletedNitric BioTherapeuticsMar 201225
NCT01433107Tinea Pedis · China3CompletedNovartisFeb 2012290
NCT01286701Lecithin Cholesterol Acyltransferase Deficiency · Canada1CompletedDr. Reddy's LaboratoriesFeb 200218
NCT01286688Fasting · Canada1CompletedDr. Reddy's LaboratoriesFeb 200236
NCT01145807Onychomycosis · United States3UNKNOWNCeltic Pharma Development ServicesFeb 2012738
NCT01790165Onychomycosis2CompletedCeltic Pharma Development ServicesJan 201027
NCT01080079Onychomycosis · United States, Canada2CompletedNitric BioTherapeuticsNov 2011168
NCT00833664Healthy · United States1CompletedTeva Pharmaceutical IndustriesJan 200222
NCT00833586Healthy · United States1CompletedTeva Pharmaceutical IndustriesJan 200228
NCT00691184Onychomycosis · United States1Completednexmed-u-s-a-inc-subsidiary-of-apricus-biosciences-incJun 200556
NCT00648713Healthy · United States1CompletedViatrisMar 200436
NCT00647647Healthy · United States1CompletedViatrisMar 200436
NCT00602342Onychomycosis · United States–CompletedHikma PharmaceuticalsApr 200430
NCT00602251Onychomycosis · United States–CompletedHikma PharmaceuticalsApr 200430
NCT00459537Onychomycosis · Finland, France, Germany and more3CompletedNovartisJan 20091,029
NCT00443898Onychomycosis · United States, Canada, Iceland3CompletedNovartisJun 2008518
NCT00443820Onychomycosis · United States, France, Germany3CompletedNovartisJun 2008526
NCT00117767Tinea Capitis · United States3CompletedNovartisMar 2006720
NCT00117754Tinea Capitis · United States3CompletedNovartis720
NCT00002394Candidiasis, Oral · United States–CompletedNovartis30

How it is read

Names in the registry

  • “MOB015B”, 7 entries
  • “terbinafine”, 4 entries
  • “Terbinafine”, 3 entries
  • “Terbinafine Hydrochloride”, 3 entries
  • “Terbinafine HCl 250mg tablets”, 2 entries

Codes read as this program: P3058.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.